Denali Advisors’s Corcept Therapeutics CORT Stock Holding History

Denali Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-225,600	Closed	-$3.55M	–	262
2018 Q2	$3.55M	Sell	225,600 -20,600	-8%	-$358K	0.53%	55
2018 Q1	$4.05M	Sell	246,200 -26,800	-10%	-$497K	0.65%	54
2017 Q4	$4.93M	Buy	+273,000	New	+$4.94M	0.76%	44

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Denali Advisors's CORT Position: Q3 2018 in Review

Denali Advisors sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 225,600 shares — an estimated $3.55M sold.

Denali Advisors first reported a position in CORT in Q4 2017 and held it in 3 quarters. The position peaked at $4.93M in Q4 2017. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

Denali Advisors reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
Denali Advisors sold 225,600 Corcept Therapeutics shares in Q3 2018, an estimated $3.55M.
Denali Advisors first reported a position in Corcept Therapeutics in Q4 2017 and held it in 3 quarters.
Denali Advisors's Corcept Therapeutics position peaked at $4.93M in Q4 2017.
207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on Denali Advisors's 13F filing for Q3 2018, filed 9 Oct 2018.